Alzheimers Research & Therapy

Article	Citations
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	483
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	158
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	158
Retraction Note: Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis	137
A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients	128
Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer’s disease	115
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	111
Relationship between hearing impairment and dementia and cognitive function: a Mendelian randomization study	106
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes	99
Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury	97
Kidney function, albuminuria, and their modification by genetic factors and risk of incident dementia in UK Biobank	88
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	77
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis	75
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	75
ANU-ADRI scores, tau pathology, and cognition in non-demented adults: the CABLE study	69
High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 × Tg) mouse model of Alzheimer’s disease associated with chronic platelet activation	66
Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study	66
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia	63
Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts	62
The course of primary progressive aphasia diagnosis: a cross-sectional study	62
Prevalence and modifiable risk factors for dementia in persons with intellectual disabilities	59
Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretase	58
Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer’s disease	58
Dissecting neural correlates of theory of mind and executive functions in behavioral variant frontotemporal dementia	57
Longitudinal change in ATN biomarkers in cognitively normal individuals	57

Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	56
Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases	56
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease	56
Intestinal endogenous metabolites affect neuroinflammation in 5×FAD mice by mediating “gut-brain” axis and the intervention with Chinese Medicine	55
Prognostic model for predicting Alzheimer’s disease conversion using functional connectome manifolds	53
Leading mediators of sex differences in the incidence of dementia in community-dwelling adults in the UK Biobank: a retrospective cohort study	52
Association between untreated and treated blood pressure levels and cognitive decline in community-dwelling middle-aged and older adults in China: a longitudinal study	51
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	49
A novel age-informed approach for genetic association analysis in Alzheimer’s disease	48
The impact of incident stroke on cognitive trajectories in later life	48
Enhancing magnetic resonance imaging-driven Alzheimer’s disease classification performance using generative adversarial learning	48
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum	47
Sex-specific associations of kynurenic acid with neopterin in Alzheimer’s disease	47
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	46
Gossypetin ameliorates 5xFAD spatial learning and memory through enhanced phagocytosis against Aβ	45
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting	44
Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?	43
Intermittent hypoxia treatment alleviates memory impairment in the 6-month-old APPswe/PS1dE9 mice and reduces amyloid beta accumulation and inflammation in the brain	43
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation	42
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	42
A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protoc	41
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation	41
Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update	41
Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease	41
Investigating the power of eyes open resting state EEG for assisting in dementia diagnosis	40
Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6	38
Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project	38
Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals	37
Higher performance for women than men in MRI-based Alzheimer’s disease detection	37
Mesial temporal tau in amyloid-β-negative cognitively normal older persons	37
Irregular word reading as a marker of semantic decline in Alzheimer’s disease: implications for premorbid intellectual ability measurement	37
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	36
Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis	35
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model	35
Heat-related illness and dementia: a study integrating epidemiological and experimental evidence	35
Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome	34
Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage	33
Adherence to a lifestyle intervention – just a question of self-efficacy? Analysis of the AgeWell.de-intervention against cognitive decline	33
Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an obse	33
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia	33
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	32
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	32
Brain derived β-interferon is a potential player in Alzheimer’s disease pathogenesis and cognitive impairment	32
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	32
Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials	32
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	31
Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals	31
Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology	31
Subjective cognitive concerns, APOE ε4, PTSD symptoms, and risk for dementia among older veterans	31
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease	31

Brain age as a biomarker for pathological versus healthy ageing – a REMEMBER study	31
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	31
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	30
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	30
Association between Life’s Simple 7 and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact adults: the CABLE study	30
Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease	29
Anticipated reactions to learning Alzheimer’s disease biomarker results	29
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	29
Experiences of and recommendations on clinical trial design in Alzheimer’s disease from the participant’s point of view: a mixed-methods study in two clinical trial centers in the Netherlands	29
Association of outer retinal and choroidal alterations with neuroimaging and clinical features in posterior cortical atrophy	29
APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia	29
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	29
Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer’s disease progression: a systematic review	28
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912	28
Association between glycemic status and all-cause mortality among individuals with dementia: a nationwide cohort study	28
The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy	28
Mitochondrial SOS: how mtDNA may act as a stress signal in Alzheimer’s disease	28
Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort	28
High-intensity walking in midlife is associated with improved memory in physically capable older adults	27
Nonlinear changes in delayed functional network topology in Alzheimer’s disease: relationship with amyloid and tau pathology	27
Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort	27
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease	27
Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort	26
Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease	26
A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers	26
Prodromal frontotemporal dementia: clinical features and predictors of progression	26
Variables associated with cognitive function: an exposome-wide and mendelian randomization analysis	25
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease	25
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	24
Association of cortical and subcortical microstructure with disease severity: impact on cognitive decline and language impairments in frontotemporal lobar degeneration	24
Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer’s disease: a strategy integrating multi-omics analysis with explainable machine learning	24
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	23
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	23
Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling	23
Longitudinal change in hippocampal and dorsal anterior insulae functional connectivity in subjective cognitive decline	23
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	23
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	23
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	23
Early activation of Toll-like receptor-3 reduces the pathological progression of Alzheimer’s disease in APP/PS1 mouse	23
ADataViewer: exploring semantically harmonized Alzheimer’s disease cohort datasets	22
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile	22
Photobiomodulation in experimental models of Alzheimer’s disease: state-of-the-art and translational perspectives	22
Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE	22
The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury	22
Shared genetic risk loci between Alzheimer’s disease and related dementias, Parkinson’s disease, and amyotrophic lateral sclerosis	22
A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau	21
Steeper memory decline after COVID-19 lockdown measures	21
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	21
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	21
Altered metabolic connectivity within the limbic cortico-striato-thalamo-cortical circuit in presymptomatic and symptomatic behavioral variant frontotemporal dementia	21
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrie	20
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	20
Correction: Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer’s disease and mild cognitive impairment	20
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	20
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline	20
Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography	20
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease	20
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	20
Correction: Cortical microstructure in primary progressive aphasia: a multicenter study	20
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	20
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles	20
The efficacy of exergaming in people with major neurocognitive disorder residing in long-term care facilities: a pilot randomized controlled trial	20
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	20
Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle?	20
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial	20
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	19
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	19
Correction: Polygenic effects on the risk of Alzheimer’s disease in the Japanese population	19
Differential response to donepezil in MRI subtypes of mild cognitive impairment	19
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease	19
Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease	18
Association of antihypertensive drug target genes with alzheimer’s disease: a mendelian randomization study	18
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	18
CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease	18
Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer’s disease	18
Retinal optical coherence tomography intensity spatial correlation features as new biomarkers for confirmed Alzheimer’s disease	18
Targeting early tau pathology: probiotic diet enhances cognitive function and reduces inflammation in a preclinical Alzheimer’s model	18
Equine-assisted services for people living with dementia: a systematic review	17
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation	17
Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer’s disease: a potential early sign of AD	17

Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	17
A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease	17
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	17
Subjective cognitive decline is a better marker for future cognitive decline in females than in males	17
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians	17
Research attitudes in families of individuals with Down syndrome: importance for clinical trials	17
Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)	16
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	16
Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain	16
Different associations between body mass index and Alzheimer’s markers depending on metabolic health	16
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	16
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer’s disease	16
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease	16
Serum zinc levels and in vivo beta-amyloid deposition in the human brain	16
The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer’s disease continuum participants	16
Home-based transcranial alternating current stimulation (tACS) in Alzheimer’s disease: rationale and study design	16
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns	16
Amyloid β oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction	16
Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer’s-type dementia therapies	16
APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly	15
Association between depression and young-onset dementia in middle-aged women	15
CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease	15
Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer’s disease continuum in the prospective COGICARE study	15
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways	15
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	15
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease	15
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	15
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults	15
Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [18F]flortaucipir study	15
The role of perfusion, grey matter volume and behavioural phenotypes in the data-driven classification of cognitive syndromes	14
Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities	14
Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results	14
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	14
Phenotype and imaging features associated with APP duplications	14
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease	14
Evaluating the inter-species transmission risk of amyloid beta peptide aggregates via ingestion	14
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6	14
Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment	14
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217	14
Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay	14
The neural substrates of transdiagnostic cognitive-linguistic heterogeneity in primary progressive aphasia	14
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias	14
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	14
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	14
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	14
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	13
Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX	13
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice	13
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial	13
Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults	13
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease	13
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	13
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	13
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk	13
Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status	13
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	13
Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies	13
In vivo cortical diffusion imaging relates to Alzheimer’s disease neuropathology	13
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	13
Proof-of-concept recall-by-genotype study of extremely low and high Alzheimer’s polygenic risk reveals autobiographical deficits and cingulate cortex correlates	13
The effects of exercise programs on cognition, activities of daily living, and neuropsychiatric symptoms in community-dwelling people with dementia—a systematic review	13
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design	13
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	13
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort	13
Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppNL−G−F knock-in Alzheimer mice	13
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	12
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	12
Investigating the relationship between BMI across adulthood and late life brain pathologies	12
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	12
Neuropsychological test performance of former American football players	12
Serum neurofilament light chain level as a predictor of cognitive stage transition	12
Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults	12
Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients	12
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort	12
Emotional prosody recognition is impaired in Alzheimer’s disease	12
Diagnostic accuracy of research criteria for prodromal frontotemporal dementia	12
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers	11
Aη-α and Aη-β peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo	11
Amyloid deposition and its association with depressive symptoms and cognitive functions in late-life depression: a longitudinal study using amyloid-β PET images and neuropsychological measurements	11
Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial	11
Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline	11
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	11
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease	11
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease	11
Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers	11
GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe	11
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	11
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease	11
The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort	11
Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics	11
Longitudinal evidence for a mutually reinforcing relationship between white matter hyperintensities and cortical thickness in cognitively unimpaired older adults	11
Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer’s disease spectrum	11
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals	11
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts	11
Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies	11